Novo Nordisk analyst signal

A widely shared analyst note put a fresh buy call on Novo Nordisk this week, pointing investors to the company’s new Wegovy pill as the next near-term catalyst. (novonordisk.com) The post circulating on X described Novo as an “SB1 Buy” with a DKK 280 price target and argued the stock was trading at a roughly 20% to 25% discount to obesity-drug peers. Novo’s U.S.-listed shares closed at $40.93 on April 16, after rising 0.29% that day, with the stock still down about 20% year to date. (x.com) (finance.yahoo.com) (google.com) The catalyst in that call is oral Wegovy, the once-daily pill version of semaglutide that the U.S. Food and Drug Administration approved on Dec. 22, 2025 as the first oral glucagon-like peptide-1, or GLP-1, treatment for obesity. Novo said at the time that the pill would launch in early 2026. (prnewswire.com) (cnbc.com) GLP-1 drugs copy a gut hormone that helps people feel full and lowers blood sugar, and the pill matters because it removes injections from the treatment routine. CNBC reported on April 7 that early U.S. demand for Novo’s pill was bringing in patients who had delayed treatment because of needle aversion or out-of-pocket costs. (cnbc.com) Novo is trying to regain momentum after investors spent the past year focusing on Eli Lilly’s faster growth in obesity drugs and on pricing pressure in some markets. Novo’s 2025 annual report said obesity-care sales rose 26% in Danish kroner to DKK 82.3 billion, while the company’s branded global obesity-drug volume share was 59.6%. (annualreport.novonordisk.com) (cnbc.com) The social chatter also included talk of an OpenAI link, and that part is no longer just rumor. Novo Nordisk announced an official partnership with OpenAI on April 14, saying it would use the technology across drug discovery, manufacturing and commercial operations. (novonordisk.com) (cnbc.com) Reuters reported the company framed the deal as a way to move faster in finding and developing new medicines, at a time when it is trying to defend its position in the weight-loss market. Novo said the partnership includes data-governance controls and human oversight. (msn.com) (biospace.com) The analyst post and the OpenAI announcement are separate developments, but they landed in the same week and fed the same argument: that Novo has new products and new tools to counter a stock that has fallen sharply from its 2025 highs. Whether DKK 280 proves realistic will turn on pill uptake, pricing and how much ground Novo can recover against Lilly over the rest of 2026. (x.com) (google.com) (novonordisk.com)